Radiation Protection Dosimetry Advance Access originally published online on January 28, 2008
Radiation Protection Dosimetry 2007 127(1-4):449-455; doi:10.1093/rpd/ncm473
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for PU
1 US Transuranium and Uranium Registries, College of Pharmacy, Washington State University, 1845 Terminal Drive, Suite 201, Richland, WA 99354, USA
2 Department of Mechanical, Industrial and Nuclear Engineering, University of Cincinnati, 598 Rhodes Hall, Cincinnati, OH 45221, USA
3 Pacific Northwest National Laboratory, PO Box 999, Richland, WA 99354, USA
* Corresponding author: tjames{at}tricity.wsu.edu
This whole body donation case (USTUR Registrant) involved a single acute inhalation of an acidic Pu(NO3)4 solution in the form of an aerosol ‘mist’. Chelation treatment with intravenously (i.v.) Ca-EDTA was initiated on the day of the intake, and continued intermittently over 6 months. After 2.5 y with no further treatment, a course of i.v. Ca-DTPA was administered. A total of 400 measurements of 239+240Pu excreted in urine were recorded; starting on the first day (both before and during the initial Ca-EDTA chelation) and continuing for 37 y. This sampling included all intervals of chelation. In addition, 91 measurements of 239+240Pu-in-feces were recorded over this whole period. The Registrant died about 38 y after the intake, at age 79 y, with extensive carcinomatosis secondary to adenocarcinoma of the prostate gland. At autopsy, all major soft tissue organs were harvested for radiochemical analyses of their 238Pu, 239+240Pu and 241Am content. Also, all types of bone (comprising about half the skeleton) were harvested for radiochemical analyses, as well as samples of skin, subcutaneous fat and muscle. This comprehensive data set has been applied to derive ‘chelation-enhanced’ transfer rates in the ICRP Publication 67 plutonium biokinetic model, representing the behaviour of blood-borne and tissue-incorporated plutonium during intervals of therapy. The resulting model of the separate effects of i.v. Ca-EDTA and Ca-DTPA chelation shows that the therapy administered in this case succeeded in reducing substantially the long-term burden of plutonium in all body organs, except for the lungs. The calculated reductions in organ content at the time of death are 
40% for the liver, 60% for other soft tissues (muscle, skin, glands, etc.), 50% for the kidneys and 50% for the skeleton. Essentially, all of the substantial reduction in skeletal burden occurred in trabecular bone. This modelling exercise demonstrated that 3-y-delayed Ca-DTPA therapy was as effective as promptly administered Ca-EDTA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. P. Lynch, S. Y. Tolmachev, and A. C. James Estimating 241Am activity in the body: comparison of direct measurements and radiochemical analyses Radiat Prot Dosimetry, June 1, 2009; 134(2): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Breustedt, E. Blanchardon, P. Berard, P. Fritsch, A. Giussani, M. A. Lopez, A. Luciani, D. Nosske, J. Piechowski, J. Schimmelpfeng, et al. BIOKINETIC MODELLING OF DTPA DECORPORATION THERAPY: THE CONRAD APPROACH Radiat Prot Dosimetry, April 7, 2009; (2009) ncp058v1. [Abstract] [Full Text] [PDF]
|
|